Indiana University
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Indiana University sits in the top decile of US sponsors by registered trial count (#38 of 15,742 sponsors by registered trial count).
Indiana University: 890 sponsored US clinical trials, 156 recruiting.
Indiana University sponsors 890 registered US clinical trials on ClinicalTrials.gov, 156 of them currently recruiting, and 561 completed. 104 of these trials are in Phase 3-4 (later-stage) and 126 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Alzheimer Disease, with 11 trials.
Top-decile sponsor footprint
Indiana University ranks in the top decile of sponsors by registered trial count (#38 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
561 of 688 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
890 total, page 17 of 18
Growth of Airways and Lung Tissues in Premature and Healthy Infants
NCT00419588
Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer
NCT00375310
Vaginal Cleansing at Cesarean Delivery to Reduce Infection: A Randomized, Controlled Trial
NCT00386477
Study of Catheter-related Infections Using Antibiotic-coated Versus Conventional Catheters in Children
NCT00370149
Role of Exenatide in NASH-a Pilot Study
NCT00650546
EUS-CPN: A Retrospective Review
NCT00577564
e-CHAMP: Enhancing Care for Hospitalized Older Adults With Memory Problems
NCT00182832
Clinical Impact of EUS in Staging NSCLC
NCT00577746
Lung Cancer Location: a Repository
NCT00578084
Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
NCT01673009
Chromocolonoscopy for the Detection of Flat Adenomas in Routine Colorectal Cancer Screening.
NCT00245492
Value of Fecal Calprotectin
NCT00577928
The Effect of Concomitant Administration of Erythromycin and Diltiazem on CYP3A Activity in Healthy Volunteers
NCT00318201
Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma
NCT00314873
A Pilot Study of Fish Oil Supplementation in Hemodialysis Patients
NCT00308295
Prevalence of Lymphoma in IBD
NCT00577538
Protein and Energy Metabolism in Pediatric Crohn's Disease
NCT00583232
Protein Metabolism in Newly Diagnosed Pediatric Inflammatory Bowel Disease
NCT00586352
Cholecalciferol Versus Doxercalciferol in the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease
NCT00285467
Spironolactone to Decrease Potassium Wasting in Hypercalciurics on Thiazides Diuretics
NCT00276289
Chromoendoscopy for Ulcerative Colitis Surveillance
NCT00274209
Quality of Life in African-American or Caucasian Female Breast Cancer Survivors
NCT00268502
Effects of RG1068 (Secretin) on Information Processing in Schizophrenia
NCT00235274
Pilot Study Using Neoadj Chemo-Rad & EGFR-tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer
NCT00243854
T Wave Alternans in Hemodialysis
NCT00296543
A Feasibility Study of Smoking Cessation Program in Radiation Oncology
NCT00236288
Prevention of Atrial Fibrillation Following Esophagectomy
NCT00420017
Evaluating the Effectiveness of Aripiprazole and D-Cycloserine to Treat Symptoms Associated With Autism
NCT00198107
Efficacy and Safety Study of Clozapine Augmented by Atomoxetine Versus Clozapine Augmented by Placebo in Patients With Chronic Resistant Schizophrenia
NCT00216281
Use of Celecoxib in Patients With Intraductal Papillary Mucinous Neoplasms (IPMNs)
NCT00198081
Long Term Effects of Diabetes of Very Young Children
NCT00707629
Memantine Augmentation of Lamotrigine Incomplete-Response in Bipolar Depression
NCT00305578
Hypertension in Hemodialysis Patients (Aim 3)
NCT00582114
Using Computers to Assist in the Treatment of Asthma in a Pediatric Setting
NCT01312805
Treating the Endothelium to Restore Insulin Sensitivity
NCT00402194
Metabolic Response to Infliximab in Pediatric Ulcerative Colitis
NCT00586807
Risk of Asthma in Infants With Atopic Dermatitis
NCT00459576
Phase I, Pharmacokinetic, Pharmacodynamic Trial of PTK787 and Paclitaxel in Combination for Advanced Solid Tumors
NCT00731861
A Prospective Study of Thin Prep Versus Papanicolau in Suspected Malignant Lesions During Endoscopic Ultrasound (EUS)
NCT00716196
Safety Study of the Drug RG1068 in Patients With Obsessive Compulsive Disorder
NCT00216294
Absorption of Brimonidine Ophthalmic Solution in the Aqueous Humor of Cataract Patients
NCT00352807
Assessment Of The Effects Of Short and Long Term Use Of CPAP
NCT00592631
Pharmacogenetics as a Predictor of Toxicity in Pre-Menopausal Women Receiving Doxorubicin and Cyclophosphamide in Early Breast Cancer
NCT00352872
A Study of Aripiprazole in Children and Adolescents With Aspergers and Pervasive Developmental Disorder.
NCT00198055
Prevention of Atrial Fibrillation Following Noncardiac Thoracic Surgery
NCT00127712
Outcomes of Intraoperative 5-Fluorouracil Versus Mitomycin C
NCT00346489
Stepped Care for Depression and Musculoskeletal Pain
NCT00118430
Telephone Assessment and Skill-Building Kit (TASK): A New Program for Family Caregivers of Stroke Survivors
NCT00264745
Dose Escalation Study for Primary Hepatocellular Carcinoma
NCT00243841
The Effects of Obesity and Protein Intake on the Kidney
NCT00244790
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 56 |
| Phase 2 | 70 |
| Phase 3 | 28 |
| Phase 4 | 76 |
Therapeutic Areas
What is open in the Indiana University pipeline
156 recruiting of 890 indexed (18% open); 561 completed (63%).
Phase mix: 104 late (III/IV) vs 126 early (I/II) (balanced across stages).
Top condition: Alzheimer Disease (11 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Indiana University: open-pipeline peers nationwide
Peers matched on 890 registered trials and 18% open enrollment, not the therapeutic-area sidebar.
Indiana University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 890 trials (± recruiting share)
- University of California, Los Angeles · 897 trials · 18% recruiting
- Hoffmann-La Roche · 909 trials · 8% recruiting
- Brigham and Women's Hospital · 937 trials · 15% recruiting
- University of Texas Southwestern Medical Center · 837 trials · 19% recruiting
Sponsors near 18% open enrollment (± trial volume)
- Edwards Lifesciences · 18% recruiting · 57 trials
- University of South Florida · 17% recruiting · 252 trials
- VA Office of Research and Development · 17% recruiting · 1,668 trials
- ConvaTec · 18% recruiting · 17 trials
Related
What to do with this Indiana University page
890 registered trials is a research-attention snapshot, not an endorsement of Indiana University or any single study.
- 156 of Indiana University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Alzheimer Disease is the condition Indiana University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Alzheimer Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Indiana University pipeline card: 890 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.